You are here: Industry Insights > Lilly

News List

Lilly to provide antibody therapies at Indiana hospitals for treating COVID-19 pharmaceutical-business-review
February 05, 2021
Eli Lilly and Company (Lilly) has joined hands with local health systems in the US state of Indiana to provide antibody therapies through dedicated infusion centre locations that will offer treatments for patients with COVID-19.
Innovent and Lilly Jointly Announce the Approval of TYVYT® (sintilimab injection) by China NMPA in Combination with Pemetrexed and Platinum Chemotherapy as First-Line Therapy for Nonsquamous Non-Small prnasia
February 03, 2021
Innovent Biologics, Inc., a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, and Eli Lilly and Company, today ...
Lilly, US health systems partner to set up Covid-19 antibody infusion centres pharmaceutical-technology
February 03, 2021
Eli Lilly and Company and local health systems have partnered to establish dedicated infusion centre locations in the US to offer Hoosiers with access to vital Covid-19 treatments.
Lilly Acquires Asahi Kasei’s Chronic Pain Candidate contractpharma
February 02, 2021
Eli Lilly and Co. and Asahi Kasei Pharma entered a license agreement under which Lilly will acquire the exclusive rights for AK1780 from Asahi Kasei Pharma.
Lilly’s antibodies bamlanivimab and etesevimab show promise against COVID-19 pharmatimes
January 29, 2021
Eli Lilly’s neutralising antibodies bamlanivimab and etesevimab significantly reduced COVID-19-related hospitalisations and deaths in recently diagnosed, high-risk COVID-19 patients.
Lilly, Vir and GSK collaborate for trial of Covid-19 therapies pharmaceutical-technology
January 28, 2021
Eli Lilly and Company, Vir Biotechnology, and GlaxoSmithKline (GSK) have entered into a partnership to analyse a combination of two therapies in low-risk patients with mild to moderate Covid-19.
Lilly Completes $1B Acquisition of Prevail contractpharma
January 25, 2021
Eli Lilly and Company has successfully completed its $1.04 billion acquisition of Prevail Therapeutics Inc., adding a new modality for drug discovery and development at Lilly, and extending research efforts through the creation of a gene therapy ...
Lilly and Merus partner to develop T-Cell re-directing antibody therapies pharmaceutical-technology
January 21, 2021
Research and development group of Eli Lilly and Company, Loxo Oncology at Lilly, and clinical-stage oncology company Merus have announced a research collaboration and exclusive license agreement to develop T-Cell re-directing bispecific antibodies.
Financial Report； Lilly contractpharma
October 29, 2020
Comments: Key growth products launched since 2014, consisting of Taltz, Trulicity, Verzenio, Jardiance, Olumiant, Emgality, Tyvyt, Baqsimi, Cyramza, Retevmo and Basaglar contributed nearly 9 percentage points of revenue growth and represented ...
Lilly and Amgen to collaborate for manufacturing COVID-19 antibody therapies expresspharma
September 18, 2020
Together, the companies hope to be able to produce many millions of doses even next year.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 25 26 Next page